With no explanation, the FDA canceled the meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC), scheduled to discuss the makeup of the 2025-2026 seasonal influenza vaccines, which could affect next year’s supply of influenza vaccine.
“I got an email from the FDA saying that our March 13 meeting has been canceled—not postponed, not delayed—canceled, with no reason given as to why, who made that decision or how it came to be made,”